The median duration of advanced disease was 17 months (mean 27 months; range 7 days-12 years). The mean cost of treatment per patients was calculated to be £7,620 (range £317-£27,860). Mean duration of in-patient stay was 32 days (0-133) and this accounted for 56% of total costs. The large majority (>80%) of the time spent as an in-patient was for the care of serious illness rather than for specific antitumour treatment. Cytotoxic drugs accounted for 9% of the total cost, compared with 8% for radiotherapy and 13% for laboratory and radiological investigations.
Following the implementation of the National Health Service Act in April 1991, commissioning authorities have had to negotiate contracts for services with providers of health. A major problem in establishing such contracts is the lack of information within the NHS regarding the use of resources and their costs. Although it should be relatively straightforward to calculate the average cost of a single operation, it is more complicated to establish the total cost of management of a patient with a chronic disease, for example, advanced cancer. However, unless direct billing for each item of service is undertaken, it is essential that accurate calculations of average costs should be made in order to establish appropriate contracts.
In parallel with this, methods for assessing the quality and benefits of care received by patients are clearly required. Only when such measures are available will it be possible to compare patient management between different centres, and to decide on appropriate allocation of finite resources. Within an individual unit, however, an analysis of the costs of managing a particular disease may given valuable insights into how best to use scarce resources. In addition, the cost effectiveness of measures designed to reduce the incidence of advanced cancer (such as the National Breast Screening Programme or the use of adjuvant systemic therapy) can only be calculated if the cost of treating patients with advanced disease is accurately known.
Patients who present with locally advanced or metastatic breast cancer and those who develop metastases at some time after their initial treatment are most likely to die from the disease. The interval between first relapse and death varies widely, ranging from only a few days to many years. Median survival after the diagnosis of relapse is approximately 2 years, but it is impossible to predict prognosis for individual patients accurately.
In this study the (n = 25) or at any time during 1990 (n = 88). The medical records of all 25 patients who had died in the first period and a random selection of records of 50 patients from the second period were examined for information regarding management of advanced breast cancer. Twenty-five patients were excluded from further analysis, 13 of whom died of other causes without ever having evidence of relapse of breast cancer. Four patients received treatment for primary breast cancer at Guy's, but treatment for advanced disease was given exclusively at other hospitals. In the remaining eight cases, care for advanced disease was shared electively with other hospitals, as the patients lived outside the local health district. Accurate information on resource usage was not available for these patients. Hence, 50 patients whose management for advanced cancer was undertaken principally at Guy's Hospital form the basis of this study. These included patients who were managed in conjunction with a hospice or home care support team and patients who presented as emergencies to other hospitals and were then referred to Guy's for subsequent management.
Detailed information was retrieved from the case records of each of the 50 patients in the study for the period between the development of advanced disease and death. For patients who had initially presented with operable disease, the date of diagnosis of distant metastasis or inoperable locoregional recurrence was taken as the onset of advanced disease. Contralateral breast tumours and operable recurrences within a conserved breast diagnosed before this time were not considered as advanced disease. For patients who presented with inoperable locally advanced disease and for those with overt metastases at the time of diagnosis, the date of presentation to the unit was taken as the date of advanced disease.
The following information was recorded for each patient: Duration of in-patient admissions, together with the principal indication for each admission; Number of out-patient visits to surgical, radiotherapy and medical oncology clinics; All surgical, radiotherapy, endocrine and chemotherapy treatments administered; All laboratory and radiological inves- (Goddard et al., 1991) . This figure is in line with the £30 cost calculated in 1988 by Goddard and Hutton based on the reports of Greene (1983) and Atherton (1984) .
Chemotherapy
The number of cycles of each chemotherapeutic regimen administered and the duration in months of each endocrine treatment was established for each patient. Current (1991) costs of drugs at Guy's Hospital were used for the calculation of total costs of chemotherapy and endocrine therapy. The 50 patients spent a total of 1,677 nights in hospital, 1,588 of which (95%) were spent on the designated oncology ward. The mean number of overnight stays in hospital was 34 (range 0-133: Table I ). In most (>80%) cases it was possible to identify a principal indication for each admission from the in-patient records and discharge summary. Bone metastases causing pain, immobility, pathological fractures, hypercalcaemia or spinal cord compression accounted for 36% of all overnight stays. In many cases patients received aIncludes: other radiographs, mammography, myelography, magnetic resonance imaging, phlebography and echocardiography. 
Discussion
In this study an attempt has been made to calculate the total usage of hospital resources and the overall cost of care for patients with advanced breast cancer managed within a specialised NHS unit. Resource usage was calculated by abstracting detailed information from case records maintained specifically by the Breast Unit and Radiotherapy Department. As has been noted by others (Hurley et al., 1992) , it is impossible to guarantee that these records were complete. However, significant underrecording of resource usage is considered unlikely.
Previous economic studies of patients with advanced breast cancer have generally focussed either on the use of hospital beds (Mattsson et al., 1979) or on the cost of out-patient cytotoxic drug administration (Friedlander & Tattersall, 1982; Rees, 1985) . Two studies, one from Australia, the other from The Netherlands, have, however, recently been published in which total resource usage has been calculated (Hurley et al., 1992; de Koning et al., 1992 be directly compared with the findings in the current study (Table V) . Mean duration of stay in hospital was somewhat longer in The Netherlands (45 days) than at Guy's (34 days). In other respects, use of resources appears remarkably similar. Costing estimates involve assumptions and are always subject to error and possible criticism in studies of this type (Hurley et al., 1992) . In some countries, standard tariffs are available and are used for costing studies (de Koning et al., 1992) . In the UK such information is not available (Rees, 1985) . The approach adopted in the current study has therefore been to calculate costs for individual components of care wherever possible. Where this was not possible, as in the case of radiotherapy costings, the best available published data for the UK was used (Goddard et al., 1991) . Because of the likelihood of errors involved in the estimation of costs, a sensitivity analysis was undertaken. Apart from the cost of in-patient stays, moderate errors in the costs of separate components of care make only small changes to the overall costs.
The overall mean cost of hospital care calculated in this study (£7,620) can be compared with results from other countries. In the United States, the cost of treatment in the last 6 months of life for breast cancer patients covered by the Medicare programme was estimated to be $15,137 at 1984 prices (Baker et al., 1991) . In the study from Australia (Hurley et al., 1992) , the median cost for 89 patients who had died with metastatic breast cancer was Aus $11,948 (1988) . The authors noted that because of skewing of costs, mean costs are higher than median costs. In that study hospital visits comprised 54% of total costs and investigations 24%.
Costs in the current study can most closely be compared with those reported from The Netherlands (de Koning et al., 1992) . Excluding the costs of Nursing home stays (which were not assessed for our patients), de Koning et al. reported a mean total cost of hospital care of US $15, 850 (approximately £8, 450) . Importantly, the proportions of total costs attributable to different areas were very closely matched. Thus, in-patient stays and clinic visits (including specialist fees) accounted for 70% of total cost at Guy's and 71% in The Netherlands. Diagnostic procedures accounted for 12% and 11% of total costs respectively.
How does the estimated cost for caring for patients with advanced breast cancer compare with the cost of treating other conditions within the NHS? Lobo and coworkers (1991) found that the cost of induction treatment for acute myelogenous leukaemia was between £15,283 and £18,740. In a study of surgical workload and cost, Ellis (1991) calculated that the in-patient treatment costs (including surgery) for transurethral prostatectomy and cholecystectomy were each in the region of £1,200.
The largest component of the total cost of managing advanced breast cancer is attributable to time spent as an (Rubens, 1991 (Borgelt et al., 1980; Gelber et al., 1981) , and has led to changes in treatment policy within the unit. It should be noted that the patients in this study first developed advanced breast cancer between 1978 and 1990.
Prevention and early detection of the complications of bone metastases would have a major impact on the overall cost of treatment. Studies are currently in progress to assess the role of bisphosphonates in this regard. If patients who are at high risk of developing bone metastases can be identified and if these agents can reduce the incidence of pathological fractures, this could lead both to improvement in quality of life for breast cancer patients and to considerable savings for the NHS. Early detection of spinal cord compression should also be a priority area for clinical research. If patients could be identified early, perhaps by the use of magnetic resonance imaging, the costs of an expensive investigation might of offset by a reduction in the time spent in hospital.
Finally, close collaboration with hospices and home care support teams can also help to reduce costs and, we believe, significantly improve quality of life for patients and their relatives. The benefit to the patients and to the NHS of such services, many of which are funded from charitable sources, is considerable.
